The Kruskal–Wallis test showed differences close to significance between NRG1 rs3934999 genotypes and the dose of risperidone per day (Chi-squared = 5.9, df = 2, p = 0.05), suggesting further investigation should be considered.
Although no significant differences were found between AG and AA ( p -adj = 0.2) or between GG and AG ( p = 0.46) on the improvement in PANSS G subscale sores, a borderline significant difference was found for GG and AA genotypes of COMT rs4680 with AA>GG ( p -adj = 0.05), suggesting that AA genotypes may have better improvements on the PANSS G subscale than GG genotypes after risperidone treatment.